• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention consists of three process improvements in the so-called multi-step Piper-Montgomery process designed especially to produce the antifolate methotrexate which is closely related to both aminopterin and folic acid. 2,4,5,6-tetraaminopyrimidine sulfite is one starting material and is usually produced in the form of the bisulfite in an acetate buffer. The present modification positively produces the hydrochloride from the bisulfite and eliminates the acetate buffer utilized in prior art processes. Subsequently, a pteridine ring is formed from the pyrimidine hydrochloride using dihydroxyacetone at pH 5.5+/-0.2 to form the second ring. This strict pH control together with the use of hydrochloride salt minus the acetate buffer assists in preferentially favoring the formation of 2,4-diamino-6-hydroxymethylpteridine. Subsequently the 6-hydroxy-methyl compound is converted to the hydrobromide acid salt and reacted with three moles of a triphenyl dibromophosphorane and phosphazine protecting groups are formed on the amine groups of the pteridine ring as the 6-hydroxymethyl group is transformed to 6-bromomethyl, a key intermediate. The present process leaves the protecting phosphazine groups on the primary amino groups to discourage side reactions during subsequent alkylation of the other major reactant, ethyl N-(p-methylaminobenzoyl)-L-glutamate. Furthermore, ethyl N-(p-methylaminobenzoyl)-L-glutamate, the other reactant, is uniquely produced for the present multi-step reaction by a process proceeding from ethyl N-(p-trifluoromethylaminobenzoyl)-L-glutamate by utilizing an alkali metal hydroxide in a lower (C1-C6) alkanol wherein the protective trifluoroacetyl groups are removed. This step uses a special mixture preferably of an alkali metal hydroxide in ethanol and optimally 1 equivalent of KOH in 20% ethanol at or below ambient temperature where the mixture is added slowly to keep the reaction pH below 9. The combination of these improvements results in the increase of an overall yield of methotrexate from the named starting reactants from about 25% to approximately 40-50%.
    公开号:SU738511A3
    申请号:SU772544151
    申请日:1977-11-16
    公开日:1980-05-30
    发明作者:А.Эллард Джеймс
    申请人:Юнайтед Стейтс Дипартмент Оф Коммерс (Фирма)；
    IPC主号:
    专利说明:

    one
    The invention relates to an improved method for the preparation of a medicinal preparation, methotrexate, which can be used in the chemical and pharmaceutical industry.
    The closest in technical essence and the achieved effect to the method of the invention is a method for producing methotrexate, which consists in the fact that sulfate 2,4,5,6-10 -tetraaminopyrimidine by barium chloride translates into its hydrochloride, the latter is added to to a solution of dioxyacetone in acetate buffer, followed by purging with 1Ba xa, treating the resulting product with hydrobromic acid in ethanol, and introducing the 2-, 4-diamino-6-hydroxymethylpteridine hydrobromide hydrate into a reaction with 3 mol of triphenyldi - 20 bromophosphorane in dimethylacetamide, removal of phosphazine groups and the addition of 2,4-diamino-6- (bromomethyl) -piperidine hydrobromide, which is further reacted with 2S (methylamino) -benzoyl-L-glutamyl diethyl ether; New acid followed by hydrolysis and release of the target product 1. The yield of the target product is l25%., 30
    The disadvantage of this method is the low yield of the target product.
    The purpose of the present invention is to increase the yield of the final product.
    The goal is achieved by the method of producing methotrexate, which consists in the fact that 2,4,5,6-tetraaminopyrimidine sulfite is acted upon by hydrochloric acid and purged with air to transfer it to hydrochloride, the latter is introduced without reaction into dioxacetone at pH 5.5 , podcer- living by adding caustic alkali, treating the resulting product with hydrobromic acid, 2,4-diamino-6-hydroxymethylpteridine bromide, hydrated in 2,4-bis-trifenyl phosphine dibromide in dimethylacetamide, obtained 2,4-bis- (triphenyl) osphazino) -6-bromomethylpteridine is treated with diethyl ether (methylamino) -benzoyl-L-glutamic acid, followed by hydrolysis and isolation of the target product.
    权利要求:
    Claims (3)
    [1]
    The distinctive features of the method according to the invention are the use of 2,4,5, b-tetraaminopyrimidine of its sulfite in the quality of the initial salt, its transfer to the hydrochloride by the action of hydrochloric acid, the condensation of 2,4,5,6-tetraaminopyridine hydrochloride with dioxyacetone. 5.5+ tO, 2 supported by the addition of caustic alkali, using for alkylation of (methylamino) -benzoyl-L-glutamic acid diethyl ester (2,4-bis- (triphenylphosphazino) -6-bromomethyl pteridine). The method according to the invention makes it possible to increase the yield of methotrexate to 50-55% P. of p and m er 1, Synthesis of 2,4-diamino-oxymethylpteridine. 40.8 kg of tetraaminopyrimidine sulfite are exposed to 36.46 kg of concentrated hydrochloric acid and a light yellow solution is obtained that is stable at room temperature for 24 hours. It is filtered under vacuum to remove as much sulfur dioxide as possible, adjusted to pH 5.5 by adding caustic alkali, treated with an excess of dioxyacetone (40.8 kg) and intensively blown air at room temperature for 12-24 hours. The transformation is monitored by high pressure liquid chromatography (HPLC) over pteridine and pyri peaks Idina; The pH of the mixture is maintained at 5.3–5, b, by adding caustic soda until the end of the reaction, the product is isolated by precipitation at pH 5–6, preferably at 5-5. Example
    [2]
    2. Conversion of 2 ,, 4-diamino-6-hydroxymethylpteridine to a 6-methyl broth. 9.34 kg of 2,4-diamino-6-hydroxymethylpteridine is added to 3 mol of triphenyl dipromphosphorane, obtained by reaction of 27.22 kg of triphenylphosphine and 16.33 kg of bromine in dry Sdimethylacetamide) DIAC at a temperature below. The reaction takes place at a temperature below 20c in the presence of an excess of dry HBg, in the DMSch. The final product is 2,4-bis- (triphenylphosphazino) -6-bromomethylintercine. Example 3. Removal of trifluoroacetyl protecting groups. The trifluoroacetyl groups of 4- (N-methyl) -trifluoroacetamido-benzoyl-b-glutamic acid diethyl ester are removed by adding a stoichiometric amount of caustic potassium in aqueous ethanol to a solution of the ether in ethanol at an ambient temperature or below. The addition is carried out slowly to maintain the pH below 9. The reaction is carried out and is completed in 30 minutes, from measures | g the concentration of the non-hydrolyzed derivative by the HPLC method to TLC Example 4. Preparation of ethyl-N- -P- (methylamino) -benzoyl -1 glutamate l46 kg of crude ethyl N-p-acet-1mido-benzoyl -1-glutamate is added to 246 l of methylene chloride. After stirring and settling the water, conduct the mixture. A layer of methylene chloride is evaporated to 113.5 l under a slight vacuum. 51 liters of tetrahydrofuran (THF) are then added and the mixture is evaporated to-132 liters, the latter distillate containing 1.03% methylene chloride according to gas chromatography. Water analysis according to Fisher indicates a moisture content of less than 0.1%. In the reactor 2, the volume is brought to 291 liters with tetrahydrofuran, 30 kg of anhydrous granulated potassium carbonate and 51.5 kg of methyl iodide are added. The resulting slurry was stirred overnight at which time, after which 22.68 kg of powdered anhydrous potassium carbonate was again added and the reaction was completed for 55 hours at 55 ° C. Then the mixture is filtered on a Sparkler filter and evaporated in a reactor of 2 to 151 liters, first at atmospheric pressure, and then under a slight vacuum. The last distillate contains methyl iodide 2%. Denatured alcohol is then added, 75 l are distilled off in vacuo. In the reactor 2, 8.2 kg of potassium hydroxide in 22.7 liters of water and 45.4 liters of ethanol are added per liter; 1.5 h, after which the hydrolysis is completed and the pH is set to 0. Then 94.6 L of deionized water and 94.6 L of benzene are added to the reactor. The mixture is stirred and the benzene layer is decanted. The aqueous layer was extracted twice (each time 47.3 l of benzene). The benzene extracts are combined and washed with 47.3 ml of aqueous sodium hydroxide solution and then with 47.3 liters of deionized water. Then the benzene extract was evaporated to 94.6 l (in reactor 1). 94.6 L of hexane was added to the obtained product and cooled to. The precipitate was filtered and dried in a vacuum oven overnight. The yield is 32.66 kg (64.5% based on ethyl-) 1-aminobenzoyl-1-glutamate used; t, pl. 88-89C, Optical С 1.03 С 1.02 rotation (95% ЕОН) (INHCe) -23.9 -9.39 -9.43 -20.5 -10.11 ° -22.5 °, -13, 9 ° 43. 5. Preparation of ester Example of methotrexate, In an enameled reactor 1 with a capacity of 379 liters, 200.6 liters of DMAC are loaded, the humidity of which is 0.09% and 53.5 kg of triphenylphosphine. The mixture is cooled to. The bromine tank is weighed and connected to the inlet line of the reactor. A total of 37 kg of bromine are fed to the reactor (in portions) in 4 hours. Bromine is added in such a way that the temperature of the mixture is 0- + 4 ° C. 18.6 kg of pure 2,4-diamino-6-oxime tylpteridine hydrochloride bromide is charged to the reactor. The temperature is raised to 8c, and then cooled to 4 ° C. Then, over the next 12 hours, the temperature is raised to. According to GHB, 87.3% of hydroxymethylpteridine is converted to bromomethylpteridine. 25 kg of ethyl N- (p-methylamino) -benzoyl glutamate are added to the mixture and the temperature is raised to. After 22, another 3.2 kg of glutamate is added. After another 10 hours, the conversion reaches 52.3. The mixture is cooled. Then, the reactor 2 is charged with 1700 l of deionized water and the pH is set to 1.5 with hydrochloric acid and cooling water is fed into the jacket of the reactor: cooling water (lx15 s). With the operation of the reactor in the reactor 2, the entire reaction mixture from the reactor 1 is fed with pressure to the reactor 2 (, 2 hours). A precipitate is formed immediately. After stirring for 1/2 hour and maintained at a pH of 1.2, the slurry is filtered. The filtrate is pumped to a reactor with a capacity of 1890 liters of stainless steel, and the solid residue, consisting mainly of triphenylphosphine oxide, remains in the reactor. The filtrate is immediately drained back to reactor 2 and adjusted to pH 3.0 (using 6N sodium hydroxide). At pH 2.4, a solid precipitate begins to form. A minimum of mixing is used. The precipitate is then filtered on a U.S. Stoneware filter. The filtrate is returned to reactor 2 to recover additional amount of desired ester. Obtained at pH 3 47.6 kg of methotrexate ether are purified as follows. In the reactor 2 to the product load 238,5 l of methanol. Then 1567 ml of concentrated hydrochloric acid. Then 889.5 liters of water are added and the pH is adjusted with caustic alkali.
    [3]
    3. The insoluble product is filtered off on a Stoneware filter to give 4 O kg of filtrate, which contains 22.7 kg of the desired product. Claims of the method of obtaining methotrexate, including the transfer of 2,4,5,6-tetraaminopyrimidine salt to its hydrochloride, condensation of the latter with dioxyacetone, the reaction of the obtained 2 4-diamino-6-hydroxymethylpteridine with triphenyl-. dibromophosphorane in dimethylacetamide, alkylation of 6- bromomethyl derivatives of pteridine diethyl ether N- (4- (methylamino) -benzoyl-L-glutamic acid, followed by hydrolysis and release of the target product, characterized in that, in order to increase the yield of the desired product, , 5,6-tetra-pyrimidine with the action of hydrochloric acid and air blowing translate into it: hydrochloride, the latter is condensed with dioxyacetone at pH 5.5 ± 0.2, treated with hydrobromic acid, released by 2,4-diamino-6 hydrobromide -oxymethylpteridine are introduced into interaction with triphenidibromophos-forane, the resulting 2,4-bls- (triphenylphosphazino) -6-bromo; 1 methylpteridine is reacted with N- {4- (methylamino) -benzoyl -b-glutamine cyblote dithyl ester. taken into account in examination 1. 3. R. Piper .and J. A, Montgo ery A. Convenient SyntE esis of aminopterin and Homo & ogs via 6- (broomethye) -2, 4-diaminopteridine Hydro-romide. . Hef. Chem. 1974,11 p. 2) 9 (prototype).
    类似技术:
    公开号 | 公开日 | 专利标题
    SU738511A3|1980-05-30|Method of preparing metotrexate
    WO2019019795A1|2019-01-31|Method for preparing sacubitril intermediate
    AU644295B2|1993-12-02|2-aminopyrimidine-4-carboxamide derivatives, their preparation and their use in therapeutics
    US4486358A|1984-12-04|Process for producing N-phosphonomethylglycine
    SU843749A3|1981-06-30|Method of preparing 4a,9b-trans-hexahydro-gamma-carboline
    KR20030082946A|2003-10-23|Process for the preparation of 1,2-benzisoxazole-3-acetic acid
    US5239077A|1993-08-24|Highly pure amidoximes
    US7795458B2|2010-09-14|Salt of |-3-[[|-1-isobutoxymethyl-3-methylbutyl] carbamoyl] oxirane-2-carboxylic acid
    JP2825132B2|1998-11-18|New method for producing compounds
    CN111646991B|2021-08-24|Preparation method of avibactam sodium intermediate
    US4031108A|1977-06-21|2-Hydroxymethyl-3-benzyloxypyridine-6-epoxyethane
    JP3261503B2|2002-03-04|Method for producing N-substituted glycine or glycine ester and application to indigo synthesis method
    US9840468B1|2017-12-12|Methods for the preparation of 6-aminoisoquinoline
    US3948919A|1976-04-06|2-Hydroxymethyl-3-hydroxy-6-|pyridine preparation and intermediate compounds
    Effenberger et al.1988|Amino acids; 13: Investigations on the synthesis of DL-serine from α-haloacrylic acid derivatives
    JPH0641463B2|1994-06-01|Method for producing thiotetronic acid
    IE921319A1|1992-11-04|2-aminopyrimidine-4-carboxamide derivatives, their¹preparation and their application in therapy
    HU196996B|1989-02-28|Process for producing hydroxy-methyl-imidazol-2-one derivatives
    RU2234501C1|2004-08-20|Method for preparing 1-|-piperazine dihydrochloride
    SU510998A3|1976-04-15|Method for producing oxymethylpyridines
    SU604486A3|1978-04-25|Method of preparing 2-oxymethyl-3-oxy-6-|-pyridine or salts thereof
    SU1558908A1|1990-04-23|Method of obtaining 10-methyl-3-|acridinone
    SU929642A1|1982-05-23|Process for producing alpha, alpha-disubstituted derivatives of selenophene
    SU1194273A3|1985-11-23|Method of producing pyrbuterol or analogs thereof
    Effenberger et al.1988|Investigations on the synthesis of DL-serine from α-haloacrylic acid derivatives |
    同族专利:
    公开号 | 公开日
    AU3039377A|1979-05-17|
    US4080325A|1978-03-21|
    FR2371446A1|1978-06-16|
    GB1595337A|1981-08-12|
    CA1077477A|1980-05-13|
    NL7712154A|1978-05-19|
    IL53164A|1980-06-30|
    IL53164D0|1977-12-30|
    DE2741270A1|1978-05-18|
    GB1595338A|1981-08-12|
    JPS5398996A|1978-08-29|
    AU511019B2|1980-07-24|
    GB1595102A|1981-08-05|
    RO75303A|1980-11-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3989703A|1974-03-22|1976-11-02|Institutul Oncologic|Process of preparing N[p-{[-methyl]N10 -methylamino}-benzoyl]-glutamic acid|
    FR2270245B1|1974-03-26|1978-04-21|Inst Oncologic|US4306064A|1980-03-25|1981-12-15|Ellard James A|Synthesis of 2,4-diamino-6-hydroxymethylpteridine|
    US4421913A|1980-04-23|1983-12-20|The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services|Separation of triphenylphosphine oxide from methotrexate ester and purification of said ester|
    DE4309123C2|1993-03-22|1998-07-02|Mack Chem Pharm|Process for the preparation of 2,4-diamino-6-pteridine salts|
    US5382582A|1993-03-26|1995-01-17|Chan; Carcy L.|Methotrexate analogs and methods of using same|
    DE19503966C2|1995-02-07|1998-07-02|Mack Chem Pharm|Crystal modification of 2,4-diamino-6-hydroxymethylpteridine hydrobromide, process for its preparation and its use|
    US5698556A|1995-06-07|1997-12-16|Chan; Carcy L.|Methotrexate analogs and methods of using same|
    GB9617727D0|1996-08-23|1996-10-02|Knoll Ag|Process|
    AU736876B2|1996-12-06|2001-08-02|Amgen, Inc.|Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases|
    GB9626746D0|1996-12-23|1997-02-12|Knoll Ag|Process|
    DE19904812A1|1999-02-05|2000-08-10|Basf Ag|Process for the preparation of folic acid|
    US7829084B2|2001-01-17|2010-11-09|Trubion Pharmaceuticals, Inc.|Binding constructs and methods for use thereof|
    PL378879A1|2002-12-30|2006-05-29|Amgen Inc.|Combination therapy with co-stimulatory factors|
    US6921667B2|2003-03-07|2005-07-26|Prometheus Laboratories, Inc.|Methods for direct detection of individual methotrexate metabolites|
    US7582282B2|2003-08-29|2009-09-01|Prometheus Laboratories Inc.|Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics|
    WO2006031614A2|2004-09-10|2006-03-23|Tosk, Inc.|Reduced toxicity methotrexate formulations and methods for using the same|
    US20060286571A1|2005-04-28|2006-12-21|Prometheus Laboratories, Inc.|Methods of predicting methotrexate efficacy and toxicity|
    JP2009517402A|2005-11-28|2009-04-30|ディー． ロウェ，バーノン|Compositions useful for reducing nephrotoxicity and methods of use thereof|
    JP5504179B2|2008-03-03|2014-05-28|トスクインコーポレーティッド|Methotrexate adjuvant and method of use thereof for reducing toxicity|
    WO2010108116A1|2009-03-20|2010-09-23|Antares Pharma, Inc.|Hazardous agent injection system|
    WO2012037068A1|2010-09-13|2012-03-22|De Novo Diagnostics, Inc.|Methods for monitoring methotrexate therapy|
    US8680319B2|2010-12-03|2014-03-25|Kocak Farma Ilac Ve Kimya San. A.S|Method for producing antifolate agents having glutamic acid part in their structure|
    DK2844250T3|2012-05-01|2018-01-08|Translatum Medicus Inc|METHODS OF TREATMENT AND DIAGNOSTICATION OF EYE DISEASES CONCERNING BLINDNESS|
    CN102952137A|2012-10-08|2013-03-06|天津科创医药中间体技术生产力促进有限公司|Preparation method of 2,4-diamino-6-bromomethyl pteridine|
    CN107698592A|2016-08-09|2018-02-16|浙江海正药业股份有限公司|A kind of purifying process of methotrexatesalt|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/742,450|US4080325A|1976-11-17|1976-11-17|Synthesis of methotrexate|
    [返回顶部]